NCBiotech News

We work hard to bring you news about North Carolina’s wide-ranging life sciences community. Please feel free to share it with others. And let us know if you have something we should know about.

Nearly 200 scientists who specialize in RNA research are getting a treat this afternoon - a keynote presentation from the woman who just won the Nobel Prize in Chemistry for her work in this discipline.

Robert Schotzinger, M.D., Ph.D., president and CEO of Viamet Pharmaceuticals, has replaced Eric Ward of CropSolution as chairman of the NCBIO Board of Directors.

NCBIO is the trade association for North Carolina's bioscience industry. It has more than 150 members doing business in human and animal therapeutics, diagnostics, medical devices and agricultural and industrial biotechnology.

Sajith Wickramasekara, a student at the North Carolina School of Science and Mathematics in Durham, is one of two Southeastern regional finalists in an international competition of high school biotechnology research projects, held in Atlanta on Monday.

Wickramasekara and the other regional finalist, Johnny Fells III of Georgia, were competing in the Sanofi-Aventis International BioGENEius Challenge, conducted by the Arlington, Va.-based Biotechnology Institute.

Durham startup 410 Medical has received FDA 510(k) Clearance for its LifeFlow PLUS Blood and Fluid Infuser (LifeFlow PLUS). 
Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field, the company announced.
Pfizer announced today that it will invest an additional $500 million and add 300 more jobs to increase its newly completed gene therapy manufacturing capabilities at its 230-acre campus in Sanford, North Carolina.
Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, has signed an exclusive collaboration and license agreement with Janssen Pharmaceuticals that could be worth up to $818 million.
Seqirus, the world’s second largest influenza vaccine company, has broken ground for a $9 million expansion of its massive manufacturing facility in Holly Springs.
The North Carolina Biotechnology Center has announced the inaugural class of Pfizer-NCBiotech Distinguished Postdoctoral Fellows in Gene Therapy.
Locus Biosciences, born with the help of two loans from the North Carolina Biotechnology Center, has raised $19 million in Series A funding from major investors.

Pfizer, the global pharmaceutical giant, will expand its vaccine-manufacturing plant in Sanford with a $100 million investment in gene therapy that will add 40 jobs to its workforce.

Panaceutics, a personalized medicine and clinical nutrition company in Research Triangle Park, will partner with Florida Hospital’s Cardiovascular Institute on a new way to help patients with heart disease take all of their medicines as prescribed.

Panaceutics, a personalized medicine and clinical nutrition company in Research Triangle Park, will partner with Florida Hospital’s Cardiovascular Institute (CVI) on a new way to help patients with heart disease take all of their medicines as prescribed.

The billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit yet another milestone. The highly skilled workers at the sprawling factory southeast of Raleigh successfully produced the world’s first cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.

Achelios Therapeutics of Chapel Hill has completed a meeting with the U.S. Food and Drug Administration about a path to approval for its leading drug candidate, TOPOFEN, to treat acute and chronic migraine, a condition known for its debilitating pain.

A Virginia man has become the first person in the world to be treated for pancreatic cancer with a bio-absorbable, implantable radiation device called CivaSheet, developed by Durham-based CivaTech Oncology.

 

scroll back to top of page